X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (29) 29
Publication (9) 9
Book Chapter (5) 5
Book Review (3) 3
Newspaper Article (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (14) 14
male (8) 8
aged (7) 7
female (6) 6
middle aged (6) 6
animals (5) 5
care and treatment (5) 5
mice (5) 5
article (4) 4
cardiovascular diseases (4) 4
cardiovascular diseases - prevention & control (4) 4
diabetes (4) 4
diabetes mellitus, type 2 - complications (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
double-blind method (4) 4
follow-up studies (4) 4
inflammation (4) 4
abridged index medicus (3) 3
analysis (3) 3
brain (3) 3
cardiovascular disease (3) 3
cell biology (3) 3
cells, cultured (3) 3
clinical trials (3) 3
complications and side effects (3) 3
diabetes mellitus (3) 3
diabetes mellitus, type 2 (3) 3
disease (3) 3
fatty acids (3) 3
heart diseases (3) 3
hypoglycemic agents (3) 3
hypoglycemic agents - therapeutic use (3) 3
insulin (3) 3
insulin glargine (3) 3
life sciences (3) 3
medicine, general & internal (3) 3
microglia (3) 3
myocardial infarction (3) 3
neurosciences (3) 3
proportional hazards models (3) 3
research (3) 3
risk factors (3) 3
rodents (3) 3
treatment outcome (3) 3
610 medicine & health (2) 2
acetylation (2) 2
activation (2) 2
aggregation (2) 2
blood pressure (2) 2
cardiovascular diseases - etiology (2) 2
cardiovascular diseases - mortality (2) 2
causes of (2) 2
central nervous system (2) 2
cerebral infarction (2) 2
cholesterol (2) 2
cholesterol - blood (2) 2
clinic for endocrinology and diabetology (2) 2
death (2) 2
dentistry (2) 2
dietary supplements (2) 2
dosage and administration (2) 2
drug therapy, combination (2) 2
fatty acids, omega-3 (2) 2
fatty acids, omega-3 - therapeutic use (2) 2
frontotemporal dementia (2) 2
gene expression (2) 2
genetic aspects (2) 2
geriatrics & gerontology (2) 2
glucose intolerance (2) 2
glucose intolerance - complications (2) 2
glucose intolerance - drug therapy (2) 2
glucose tolerance (2) 2
health (2) 2
health aspects (2) 2
hypoglycemic agents - adverse effects (2) 2
in-vivo (2) 2
incidence (2) 2
inhibition (2) 2
insulin, long-acting (2) 2
insulin, long-acting - therapeutic use (2) 2
intention to treat analysis (2) 2
medical and health sciences (2) 2
medical research (2) 2
medicin och hälsovetenskap (2) 2
mental disorders (2) 2
microscopy, electron (2) 2
mutation (2) 2
neuroinflammation (2) 2
nf-κb protein (2) 2
oncology (2) 2
oxygen consumption - physiology (2) 2
pancreatic cancer (2) 2
pancreatic-cancer (2) 2
patient outcomes (2) 2
phosphorylation (2) 2
population (2) 2
protein degradation (2) 2
proteins (2) 2
radiation (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLOS BIOLOGY, ISSN 1544-9173, 02/2019, Volume 17, Issue 2, pp. e3000134 - e3000134
Journal Article
PLoS biology, 02/2019, Volume 17, Issue 2, p. e3000134
Microglia are resident immune cells that play critical roles in maintaining the normal physiology of the central nervous system (CNS). Remarkably, microglia... 
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 5503 - 5503
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 02/2018, Volume 16, Issue 2, pp. 222 - 232
KRAS mutations in non-small cell lung cancer (NSCLC) cause increased levels of DNA damage and replication stress, suggesting that inhibition of the DNA damage... 
DAMAGE RESPONSE | THERAPY | ONCOLOGY | PANCREATIC-CANCER | IN-VIVO | CELL-CYCLE | HOMOLOGOUS RECOMBINATION | RADIATION | TUMORIGENESIS | GEMCITABINE | CHECKPOINT ABROGATION | CELL BIOLOGY | Piperazines - administration & dosage | DNA Replication - drug effects | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Radiation-Sensitizing Agents - administration & dosage | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Cell Survival - drug effects | Phthalazines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Radiation-Sensitizing Agents - pharmacology | Lung Neoplasms - therapy | Pyrimidines - pharmacology | Cell Survival - radiation effects | Piperazines - pharmacology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Drug Synergism | Xenograft Model Antitumor Assays | Phthalazines - pharmacology | Carcinoma, Non-Small-Cell Lung - therapy | Pyrazoles - administration & dosage | Animals | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mutation | Cell Proliferation - radiation effects | Stresses | Chromatin | DNA damage | Lung cancer | Poly(ADP-ribose) polymerase | Catalytic activity | Stress | DNA biosynthesis | Trapping | Poly(ADP-ribose) Polymerase 1 | Depletion | Inhibitors | Radiosensitization | Exhaustion | Replication | Catalysis | Inhibition | Deoxyribonucleic acid--DNA | Tumors | Cancer | Index Medicus | radiation | Non-small cell lung cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 311 - 322
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 519 - 519
Journal Article
by Gerstein, Hertzel C and Bosch, Jackie and Dagenais, Gilles R and Díaz, Rafael and Jung, Hyejung and Maggioni, Aldo P and Pogue, Janice and Probstfield, Jeffrey and Ramachandran, Ambady and Riddle, Matthew C and Rydén, Lars E and Yusuf, Salim and Richardson, L and Diaz, R and Johnston, P and Vige, R and Birkeland, K and Budaj, A and Cardona, E and Chazova, I and Commerford, P and Danilova, L and Davies, M and Fernando, R and Fodor, G and Gilbert, R and Gomis, R and Hâncu, N and Hanefeld, M and Hildebrandt, P and Kacerovsky-Bielesz, G and Keltai, M and Kim, J.H and Krum, H and Kültürsay, H and Lanas, F and Lewis, B.S and Lonn, E and López-Jaramillo, P and Marin-Neto, J and Marre, M and McKelvie, R and McQueen, M and Mendoza, I and Morillo, C and Pan, C and Pīrāgs, V and Profozic, V and Ratner, R and Richardson, L and Rosenstock, J and Spinas, G.A and Sreenan, S and Stoel, I and Syvänne, M and Yale, J.F and Avezum, A and Bahit, M.C and Bogaty, P and Bordeleau, L and Chacόn, C and Corson, M and Harper, W.L and Halon, D and Magloire, P and Mann, J and Pavlova, V and Punthakee, Z and Silva, J and Tsang, B and Yakubovich, N and Abdallah, A and Ahmad, S and Chandra, J and Chandra, R and Cukierman-Yaffee, T and Dyal, L and Joldersma, L and MacRae, L and MacRae, S and Malik, S and Mead, A and Pasha, F and Pazmino-Canizares, J and Pohl, K and Sakalas, A and Tyrwhitt, J and Ahuad Guerrero, R and Alebuena, A and Alvarez, N and Alzogaray, M and Amuchastegui, M and Andres, M and Angos, M and Baglivo, H and Barbieri, M and Bassi, F and Bello, F and Bono, J and Bustamante Labarta, M and ... and The ORIGIN Trial Investigators and ORIGIN Trial Investigators and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Centrum för klinisk forskning, Västerås
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 4, pp. 319 - 328
In this study with a 2-by-2 factorial design, patients with cardiovascular risk factors and dysglycemia or type 2 diabetes received insulin glargine or... 
DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | THERAPY | GLARGINE | GLUCOSE CONTROL | DISEASE | RISK | PEOPLE | ENDOTHELIAL FUNCTION | BETA-CELL FUNCTION | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Incidence | Glucose Intolerance - drug therapy | Cardiovascular Diseases - epidemiology | Female | Drug Therapy, Combination | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Fasting | Blood Glucose - analysis | Double-Blind Method | Proportional Hazards Models | Hospitalization | Glucose Intolerance - complications | Insulin, Long-Acting - adverse effects | Insulin Glargine | Insulin, Long-Acting - therapeutic use | Intention to Treat Analysis | Triglycerides - blood | Fatty Acids, Omega-3 - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Insulin glargine | Patient outcomes | Causes of | Cardiovascular diseases | Risk factors | Myocardial infarction | Fees & charges | Cerebral infarction | Medical research | Stroke | Heart attacks | Statistical analysis | Diabetes mellitus | Glucose | Hypoglycemia | Fatty acids | Insulin | Glucose tolerance | Insulin resistance | Microvasculature | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Insulin, Long-Acting | Blood Glucose | Triglycerides | Glucose Intolerance | Cholesterol | Life Sciences | Hypoglycemic Agents | Diabetes Mellitus, Type 2 | Fatty Acids, Omega-3 | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article